| 摘要 |
The present invention relates to development of efficacious pharmaceutical compositions in the form of intraocular suspensions comprising an anti-angiogenic compound in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000, preferably at least 3000. |
